本ページは海外のバイオファーマ企業を対象としており、掲載情報は英語のみで提供しています。
This page is intended for overseas pharma companies and the information provided on this page is available in English only.
Partner with AbbVie Japan to bring your late-stage asset to patients in Japan
AbbVie Japan Partnering Campaign 2026
AbbVie invites biopharma companies with late‑stage assets to explore Japan-only and Japan-inclusive regional partnering opportunities.
Through focused 1:1 meetings with AbbVie Japan, we aim to advance discussions on Japan‑specific licensing opportunities aligned with AbbVie’s strategic priorities.
Scroll down to learn what makes Japan attractive for overseas biopharma and how AbbVie Japan can help you unlock the opportunity.
Don’t miss Japan! The opportunity many biopharma underestimate
World’s 4th Largest
(~$73B in 2025)
Pharmaceutical market after the US, China, and Germany 1)
29% aged 65+
Rapidly aging population driving high unmet needs 2)
Universal Health Coverage
enabling rapid nationwide access and limited financial burden on patients 3)
Rewarding schemes for innovation
Predictable and transparent regulatory and price listing pathway 3)
Japan is a premium market that offers rapid nationwide access and incentives for differentiated innovation - when approached strategically
Sources:
1) IQVIA Institute for Human Data Science. “Global Medicine Use Trends 2026” Feb 2026. https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-medicine-use-trends-2026
2) Statistics Bureau of Japan (Population Estimates as of Oct 1, 2024) https://www.stat.go.jp/english/data/jinsui/2024np/index.html
3) PMDA Updates, Summer 2025. https://www.pmda.go.jp/files/000276746.pdf
Japan moves faster than the US and EU – filing to launch
Sources:
4) Office of Pharmaceutical Industry Research. “Comparison of New Drug Approval Status and Examination Periods in Japan, the U.S. and Europe” Nov 2023. https://en.jpma.or.jp/opir/news/070/06.html
5) IQVIA Institute for Human Data Science. “Assessing Availability of New Drugs in Europe, Japan, and the U.S.” Dec 2024. https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/assessing-availability-of-new-drugs-in-europe-japan-and-the-us
AbbVie is your partner of choice
Abbvie Japan is built to unlock the full value of Japan, backed by a proven track record and fully integrated, in-house capabilities across:
- Clinical Development
- Regulatory Affairs
- Medical Affairs
- Pricing & Market Access
- Marketing and Sales
Our core therapeutics areas
Number of clinical trials in Japan by therapeutic areas
At a glance:
AbbVie Japan
Performance Highlights
We contribute to accelerating the Japan ecosystem
*IL-17/23 biologics and JAK inhibitors
**National, government‑backed initiative in Japan led by the National Cancer Center (NCC) to support overseas biotech and emerging biopharma companies with clinical development, regulatory consultations, and market entry in Japan
Sources:
6) AbbVie Japan press release. June 2025. https://www.abbvie.co.jp/content/dam/abbvie-com2/japan/documents/press-release/2025_0611.pdf
7) Copyright © 2026 IQVIA. Market defined and analyzed by Abbvie Japan based on JPM data (Feb 2026 MAT). Reprinted with permission
Enter Japan with confidence - from clinical development to market access and beyond.
Tap into our on-the-ground networks to navigate Japan’s complexities and accelerate your global success.
Our partner
Third-Party Awards & Recognitions
